Adagio Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Adagio Therapeutics, Inc. (Nasdaq: ADGI) has announced its participation in two upcoming investor conferences. Management will engage in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, at 2:50 p.m. ET. Additionally, they will hold one-on-one meetings at the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022. A live webcast of the fireside chat will be available on the company's investor website.

Adagio focuses on developing treatments for infectious diseases, particularly its lead candidate, adintrevimab, targeting COVID-19.

WALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of differentiated products for the prevention and treatment of infectious diseases, today announced participation in the following upcoming investor conferences:

• Morgan Stanley 20th Annual Global Healthcare Conference: Management will participate in a fireside chat on Monday, September 12, 2022, at 2:50 p.m. ET.
  
  
• H.C. Wainwright 24th Annual Global Investment Conference: Management will participate in 1 on 1 meetings on Tuesday, September 13, 2022.
  

A live webcast of the fireside chat will be available in the investor section of the company's website at investors.adagiotx.com and will be archived for 90 days following the presentations.

About Adagio Therapeutics
Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of differentiated products for the prevention and treatment of infectious diseases. The company is developing its lead product candidate, adintrevimab, for the prevention and treatment of COVID-19, the disease caused by the virus SARS-CoV-2 and its variants. The company is advancing proprietary antibodies targeting distinct sites with activity against all SARS-CoV-2 variants of concern to date and plans to take a combination of these antibodies into clinical trials in the first quarter of 2023. Beyond COVID-19, Adagio is leveraging its antibody discovery and development capabilities that have enabled expedited advancement of adintrevimab into clinical trials to develop therapeutic or preventative options for other infectious diseases, such as additional coronaviruses and influenza. Adintrevimab is an investigational monoclonal antibody that is not approved for use in any country. The safety and efficacy of adintrevimab have not been established. For more information, please visit www.adagiotx.com.

Contacts
Media Contact:
Tony Berry, Evoke Canale
774-317-0422
anthony.berry@evokegroup.com

Investor Contact:
Chris Brinzey, ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com

FAQ

What conferences is Adagio Therapeutics participating in September 2022?

Adagio Therapeutics will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, and the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022.

What is the schedule for the Morgan Stanley conference for Adagio?

Adagio will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, at 2:50 p.m. ET.

How can I access the webcast of Adagio's fireside chat?

The live webcast of Adagio's fireside chat will be available on the investor section of their website and archived for 90 days following the event.

What product is Adagio Therapeutics known for developing?

Adagio Therapeutics is developing adintrevimab, a monoclonal antibody aimed at preventing and treating COVID-19.

When is Adagio's clinical trial for adintrevimab expected to start?

Adagio plans to begin clinical trials for adintrevimab in the first quarter of 2023.